Eloxx Pharmaceuticals, Inc.

NasdaqCM:ELOX Stock Report

Market Cap: US$63.6m

Eloxx Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Eloxx Pharmaceuticals has been growing earnings at an average annual rate of 37.5%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 55.4% per year.

Key information

37.50%

Earnings growth rate

50.37%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate55.42%
Return on equity-22.94%
Net Marginn/a
Last Earnings Update30 Jun 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Sep 14

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX), a company focused on rare diseases, announced Wednesday that its lead candidate, ELX-02 in combination with ivacaftor, did not achieve efficacy endpoints in a Phase 2 trial involving certain patients with cystic fibrosis (CF). ELOX shares are currently on hold for trading. The study evaluated ELX-02 as monotherapy in combination with ivacaftor in Class 1 CF patients with at least one nonsense genetic mutation. According to topline data, the drug was well tolerated with no treatment-related serious adverse events. However, the trial did not achieve statistical significance for efficacy endpoints, including changes in sweat chloride concentration (SCC) and percent forced expiratory volume (FEV1) from the baseline. Given the safety and signs of clinical activity, ELOX, as previously announced, plans to start a proof-of-concept trial for ELX-02 later this year, targeting patients with the rare kidney disease, Alport syndrome.
Seeking Alpha • Aug 15

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals press release (NASDAQ:ELOX): Q2 GAAP EPS of -$0.12 in-line. As of June 30, 2022, Eloxx had unrestricted cash and cash equivalents of $30.0M. "As of June 30, 2022, the Company was in compliance with all debt covenants. If our lender does not accelerate our debt upon our failure to comply with the minimum cash covenant, we expect our current cash position will be sufficient to fund our operations into the fourth quarter of 2023," the company statement.
Analysis Article • Sep 09

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Feb 17

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The big shareholder groups in Eloxx Pharmaceuticals, Inc. ( NASDAQ:ELOX ) have power over the company. Institutions...

Revenue & Expenses Breakdown

How Eloxx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:ELOX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 260-1166
31 Mar 260-854
31 Dec 250-633
31 Dec 246-354
31 Dec 230-1799
30 Sep 230-201010
30 Jun 230-24913
31 Mar 230-311019
31 Dec 220-361123
30 Sep 220-421327
30 Jun 220-441528
31 Mar 220-701926
31 Dec 210-672122
30 Sep 210-611917
30 Jun 210-571815
31 Mar 210-291513
31 Dec 200-351514
30 Sep 200-401818
30 Jun 200-462121
31 Mar 200-532425
31 Dec 190-512426
30 Sep 190-532627
30 Jun 190-522625
31 Mar 190-512922
31 Dec 180-472620
30 Sep 180-452022
30 Jun 180-381520
31 Mar 180-29618
31 Dec 170-24316
30 Sep 170-16211
31 Dec 160-1119

Quality Earnings: ELOX is currently unprofitable.

Growing Profit Margin: ELOX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ELOX is unprofitable, but has reduced losses over the past 5 years at a rate of 37.5% per year.

Accelerating Growth: Unable to compare ELOX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ELOX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1%).

Return on Equity

High ROE: ELOX has a negative Return on Equity (-22.94%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 00:10
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eloxx Pharmaceuticals, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yun ZhongBrean Capital Historical (Janney Montgomery)
Mayank MamtaniB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity